The European Commission wants to resume the process of authorising the use of Genetically Modified Organisms (GMOs). Member states have imposed a de facto moratorium on licensing new GMOs since October 1998, because of growing public concern over the possible effects of releasing genetically modified plants into the environment. The Commission will unveil a plan aimed at regaining public trust in the system used to approve new licenses for the use of GMOs. It wants national governments to play their part in paving the way for a clearer and more comprehensive GMO strategy in Europe, and in promoting and open public debate on the issue.
As part of a shake-up of food safety regulations, the commission is keen to sort out the controversial issue of GMOs. The use of GMOs has been licensed under a 1990 directive, which is now being updated. When it is completed, probably some time in the autumn, the commission hopes to resume the process of issuing licenses for Genetically Modified Organisms, mainly plant varieties.
Under the existing legislation, 18 GMOs have been licensed for use in the EU. They include three vaccines and several modified varieties of Maize, Cotton, Rape and Chicory. Another 14 GMOs licence applications have been filed, and are awaiting approval or rejection. No new licences have been approved since October 1998, following a de facto moratorium by member states. Five states have banned some GMOs already approved.
The commission believes that the current state of uncertainty surrounding GMOs cannot continue. It wants to see a clear legal and scientific basis for approving the use of GMOs within the EU. It believes genetic engineering and biotechnology will play an important role in the future economy of the EU and will benefit the competitiveness of European industry.
In the immediate term, Health and Consumer Affairs Commissioner, David Byrne, is planning to bring forward new rules on the labelling of GMO products in the autumn. This is aimed at maximising consumer information and choice, and at establishing legal certainty for companies involved in biotechnology, and for farmers and retailers.
